| Project/Area Number |
15K09191
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Juntendo University |
|---|
Principal Investigator |
TOGO Shinsaku 順天堂大学, 医学部, 准教授 (80365634)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
小見山 博光 順天堂大学, 医学部, 非常勤講師 (30348982)
|
|---|
| Research Collaborator |
NAMBA Yukiko 順天堂大学, 医学部, 助教
MINIWAN Torafu 順天堂大学, 医学部, 研究員
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 循環腫瘍細胞 / テロメスキャン / 上皮間葉転換 / 非小細胞肺がん / 癌幹細胞 / 肺癌 / 非小細胞肺癌 / テロメアーゼ |
|---|
| Outline of Final Research Achievements |
Circulating tumor cells (CTCs) have a crucial role in the clinical outcome of cancer patients. The new telomerase-specific replication-selective adenovirus TelomeScan F35 (OBP-1101) can detect EMT-CTC without the detection based on epithelial markers. We measured the CTC from NSCLC patients showed mesenchymal phenotype CTC (EMT-CTC). Peripheral venous blood samples and clinicopathological data were collected from 123 NSCLC patients. The sensitivity of CTC detection was 69.1% and among the EMT-CTC samples, 46% were vimentin positive and 39.0% of non-EMT-CTC samples were EpCAM positive. Patients testing positive for EMT-CTCs at baseline had poor response to chemotherapy and decreased progression-free survival in comparison to those testing negative. TelomeScan F35 is a highly sensitive CTC detection system and will be a useful screening tool for early diagnosis of NSCLC patients. Mesenchymal-phenotype CTCs are crucial indicators of chemotherapeutic efficacy in NSCLC patients.
|
